Published in Pharma Law Weekly, October 10th, 2006
On a pro forma basis, fourth quarter net earnings were $62.2 million, or $0.50 per share, compared to pro forma net earnings of $59.2 million, or $0.47 per share, in the same quarter last year. Foreign currency translation increased sales by 2% and earnings per share by 1 cent in the quarter, and the impact of stock compensation and SFAS No. 123R,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.